Drug profile · INN
carglumic acid
CARBAGLU
carglumic acid (CARBAGLU) is a carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — carglumic acid
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
carglumic acid (CARBAGLU) is a carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator
Primary target: Carbamoyl-phosphate synthase [ammonia], mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is carglumic acid?
carglumic acid (CARBAGLU) is a carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for carglumic acid?
CARBAGLU is a marketed brand name for carglumic acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of carglumic acid?
carglumic acid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.